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Background: The historical basis and contemporary evidence for the use of immune strategies for prevention of
malignancies are reviewed. Emphasis is focussed on the Febrile Infections and Melanoma (FEBIM) study on melanoma
and on malignancies that seem to be related to an overexpression of human endogenous retrovirus K (HERV-K).
Discussion: It is claimed that, as a result of recent observational studies, measures for prevention of some malignancies
such as melanoma and certain forms of leukaemia are already at hand: vaccination with Bacille Calmette-Guérin (BCG)
of new-borns and vaccination with the yellow fever 17D (YFV) vaccine of adults. While the evidence of their benefit for
prevention of malignancies requires substantiation, the observations that vaccinations with BCG and/or vaccinia early
in life improved the outcome of patients after surgical therapy of melanoma are of practical relevance as the survival
advantage conferred by prior vaccination is greater than any contemporary adjuvant therapy.
Summary: The reviewed findings open a debate as to whether controlled vaccination studies should be conducted in
patients and/or regions for whom/where they are needed most urgently. A study proposal is made and discussed. If
protection is confirmed, the development of novel recombinant vaccines with wider ranges of protection based,
most likely, on BCG, YFV or vaccinia, could be attempted.
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As a young man, Peregrine Laziosi (1260–1345, Figure 1)
developed a large swelling on a leg (accounts differ as to
which leg), which was diagnosed as cancer. The lesion
ulcerated and the stench – a sure sign of infection – was
said to be so overpowering that his friends could not
bear to stay with him for long. Amputation seemed the
only option but, when the surgeons came to operate, the
tumour was found to be in regression and it eventually
healed completely. He had no recurrence of the cancer,
lived to be 85 years of age, was canonized as Saint Peregrine
in 1726 and is recognized by the Roman Catholic Church
as the Patron Saint of cancer patients [1]. This is just one
example of reports, over past centuries, of the spontaneous* Correspondence: Bernd-Krone@t-online.de
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unless otherwise stated.remission and even complete resolution of cancers follow-
ing some form of infection [2-9].
In 1875 Campbell de Morgan, a surgeon at the Middlesex
Hospital in London, reported that regressions and remis-
sions of cancers sometimes occurred after post-operative
infections, particularly the streptococcal infection erysipelas
[10]. De Morgan wrote, “this is an occasional event which
is very important as it encourages us to hope that a cure
may yet be found for the disease.” In the light of recent
advances in the immunology of cancer the time may well
be approaching when an elucidation of the mechanisms
underlying this ‘occasional event’ could lead to advances
in the prevention and therapy of this widespread disease.
Campbell de Morgan’s observation that remissions
sometimes occurred after post-operative streptococcal
infections inspired some workers to undertake the
risky procedure of deliberately inducing erysipelas in
cancer patients. Subsequently, an American surgeon,
William Coley, developed bacteria-free extracts of strepto-
cocci and other bacteria (“Coley toxins”) and reportedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 St. Peregrine (1260–1345).
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sarcomas, between 1881 and 1936 [11-13]. Unfortunately
Coley, a mild mannered and unassuming gentleman, did
not adhere to rigorous scientific protocols in his studies
and he was marginalized by forceful personalities advo-
cating radiotherapy. Notwithstanding, an analysis of his
results with cancer deemed inoperable undertaken in
1994 revealed a remission rate of 64% and a five-year
survival rate of 44%, results equal to or better than those
with modern therapies [14]. There have been several
more studies on this topic [15-23], but the evidence for
the effectiveness of this therapeutic approach remains
disputed.
The implication of postoperative infections for the prog-
nosis of cancer patients has been investigated in numerous
comparative studies, some of which demonstrated a better
prognosis for patients who had a postoperative infection
compared to patients without infections [24-33]. A recent
study, for example, on the effect of post-operative infection
on outcome after surgery for osteosarcoma showed that
the 10-year survival among those who developed deep
tissue infection within one year of surgery was 84.5%,compared to 62.3% in those who did not develop infec-
tions (p = 0.017) [34]. Many of the earlier studies did, how-
ever, have severe methodological flaws and the results
were quite heterogeneous and contradictory.
There has, in recent years, been a great upsurge of
interest in the immunology of cancer and it has become
clear that tumours are heterogeneous structures that,
during their development and growth, become ‘sculpted’
or ‘edited’ by immune responses and, as a result, pass
through the ‘three E’s’ of elimination, equilibration and
escape [35]. Even when a tumour is large enough to
present clinically, the immunoediting continues in a
Darwinian fashion with selection of cells expressing novel
antigens which avoid recognition by the induced immune
responses [36], explaining the short-lived effects of immu-
notherapeutic strategies based on single, or a few, tumour
antigens.
It is also now appreciated that chronic inflammation is
an essential element of cancers and it has indeed been
termed ‘the other half of the tumour’ [37]. The normal
healing process relies on inflammation, collagen produc-
tion, angiogenesis and cell proliferation and, in a descrip-
tion of the similarities between tumour stroma formation
and wound healing, tumours have been referred to
as “wounds that do not heal” [38], while in 1972 Sir
Alexander Haddow suggested that tumour growth is
the result of overhealing [39]. In addition, chronic
inflammation has been linked to the generation of
local and general patterns of immune suppression that pro-
tect tumours from immune recognition and attack [40].
Numerous attempts have been made in recent years to
develop immunotherapeutic procedures for established
cancers, though of greatly varying efficacy and cost. Much
less work has been conducted on preventive immune
strategies and, with the notable exception of human
papilloma virus vaccine for the prevention of cervical
cancer, no vaccines specifically for the prevention of
cancer are in routine use. The subject of this review,
however, is the possible use of available vaccines developed
for the prevention of common infectious diseases to reduce
the risk of at least some cancers.
Infections and cancer
The relationship between infection, and associated inflam-
mation, and cancer is a complex and paradoxical one and
there are several well described examples of cancer being
the direct consequence of infection [41]. Around 2 million
of the 12.7 million new cancer cases worldwide in 2008
(16.1%) were assumed to be related to infection, princi-
pally Helicobacter pylori, hepatitis viruses, and the human
papilloma virus, with a higher proportion in developing
countries (22.9%) than in developed ones (7.4%) [42].
The large majority of cases of cancer, especially those
in the developed nations, are therefore not caused by
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that a history of certain infections and environmental
exposure to certain populations of micro-organisms, as
well as some types of vaccination, may induce patterns
of immune reactivity that reduce the risk of at least
some cancers. It has, for example, been claimed that
while certain chronic infections predispose to cancer,
acute infections are antagonistic [43], and that life-style
factors leading to exposure of infants to acute infections,
such as attendance at day-care units, lowers the risk of
acute lymphoblastic leukaemia and melanoma [44,45].
Similar observations on acute lymphoblastic leukaemia in
childhood had been made previously in a case–control
study [46].
A study of an adult population in Italy demonstrated
an association between a history of common childhood
infectious diseases (measles, chickenpox, rubella, mumps
and pertussis) and the risk of developing chronic lymph-
atic leukaemia (CLL), with a strong inverse relationship
between the risk of CLL and the number of infections
(p = 0.002) [47]. In view of this cumulative protection
from different infectious agents, the authors concluded
that an explanation based on the ‘hygiene hypothesis’
was more likely than an anti-cancer effect of the viruses.
Despite a wealth of epidemiological studies on infections
and cancer risk the case seems, however, to be unresolved.
Another, though possibly related, example of an apparent
protective environmental effect on cancer is provided by
the association of exposure to cattle in the dairy farming
industry that apparently protects against several types of
cancer, with statistically significant associations for lung,
bladder, pancreatic, and oesophageal cancer [48]. The de-
gree of apparent protection is related to the intensity of
the exposure (the number of cattle to which the farmers
were exposed) but wanes when the farmers change to
other occupations. These findings were confirmed in a
high-quality study in Finland [49], and in a meta-analysis
of published reports [50]. Although it has been claimed
that the agents conferring protection are endotoxins that
are present in the dust derived from cattle faeces [51], it is
equally likely that apparent protection is mediated by
various genera and species of actinomycetes, which are
likewise present, and at high densities, in cowsheds. There
were also earlier investigations suggesting that persons
who are exposed to endotoxins in other occupations like-
wise have a lower cancer risk [52].
‘Darwinian medicine’
The risk of developing cancer is rising globally, especially
in the industrially developed nations where only one sixth
of the human population reside, yet almost half the cases
of cancer occur [53]. While cancer incidence rates are
mostly higher in developed as compared with developing
countries, the latter show a higher secular increase inincident rates. This rise has been attributed to an increas-
ing portion of the population reaching a more advanced
age but, as an increase is also seen in cancers affecting
younger people such as melanoma [54,55], this may be
only part of the explanation. The rising trend commenced
early in the 20th century, coinciding with the massive
recession of the major plagues, notably smallpox and tu-
berculosis, as well as of other serious infectious diseases
[56]. The roles that infections seem to exert on cancer and
cancer risk can be either beneficial or detrimental and,
since there is clearly an involvement of other environmen-
tal and genetic factors a weakness of many studies is that
corrections for the influence of these factors were not
made so that the role of infections is still unresolved.
Moreover, there has also been an increase in the inci-
dence of several classes of disease associated with chronic
inflammation in the developed nations. These include
asthma, allergic disorders, vasculitis, neurodegenerative
disorders including multiple sclerosis, autoimmune dis-
eases such as type-1 diabetes and inflammatory bowel
disease [57]. It is noteworthy that all these disorders are
associated with chronic inflammation attributable to
dysregulated immune responses [58]. The immunological
anomalies underlying these diseases may also be involved
in at least some forms of cancer [59], although it remains
to be determined whether such inflammation contributes
to the incidence of cancer or whether it is just a common
epiphenomenon.
From the moment of birth and even, though less dir-
ectly, from the moment of conception, a human being
is exposed to a vast range of members of the microbial
universe. It has indeed been estimated that for every
human cell in the body there are around ten micro-
organisms dwelling particularly in the intestine, the
upper respiratory tract and the skin. It is now generally
appreciated that, without underestimating the role of
genetic factors, this microbial population, the microbiome
[60,61], as well as more transient infecting agents, play a
crucial role in driving the maturation of the immune sys-
tem and the generation of complex immune regulatory
networks [62].
Human beings have evolved to ‘expect’ immunologically
effective contact with certain classes of micro-organisms,
including commensals and parasites, and exposure to at
least some of them seems to be required for the devel-
opment of a well-regulated immune system [63]. Some
experimental studies in animals gave indications that
some parasites might have a potential to reduce the risk
of cancer [64-66]. Unfortunately, many hygiene-related
factors in the industrialized nations prevent adequate
exposure to these micro-organisms which have been
termed our ‘Old Friends’ [63]. Indeed, this issue is re-
ceiving much attention within the emerging discipline
of Darwinian Medicine [62,63].
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giene is a change in the sequence in which infections
by micro-organisms occurs. An early infection by a
given micro-organism will elicit immune responses
principally to its dominant epitopes, but if the infection
occurs subsequent to infection by other micro-organisms
bearing cross-reactive epitopes, the response may well be
directed principally towards alternative, non-dominant,
epitopes with quite different consequences for the host.
The phenomenon has been termed ‘Original Antigenic
Sin’ [67], and we have previously postulated that the in-
creased incidence of multiple sclerosis in the developed
nations over the last 150 years is a consequence of an
altered immune reactivity to the Epstein-Barr virus, a
strong risk factor for the disease when it is acquired at a
later period in life (late teens or early adult life) rather
than in infancy [59,68]. The immune system of each indi-
vidual therefore develops its distinctive ‘biography’ so that
the response to a given antigenic challenge may vary from
one individual to another with, for example, generation of
regulatory T-cells in one individual and proliferation of
various effector T cells in another [68]. This raises the
question of whether the ‘biography’, especially if affected
by hygiene-related factors, is also a risk-determining factor
for cancer and whether this risk can be reduced by alter-
ing the biography by, for example, appropriate vaccination
strategies.
The case of vaccination with Bacille Calmette-Guérin
(BCG) and cancer risk
Naturally occurring infections and environmental ex-
posures to microbial populations provide, by their very
nature, highly unpredictable ways of preventing cancer
whereas vaccinations provide in principle a much more
rational and safer means to achieve this aim. Likewise,
despite the observations of Coley and others, thera-
peutic and/or preventive vaccines that do not induce
fever would be far more acceptable to both regulatory
authorities and patients.
BCG vaccine, a living and attenuated derivative of
Mycobacterium bovis, has been used, though with very
variable results, for the prevention of tuberculosis for
around 90 years. Being a whole bacterium with an ex-
tremely complex adjuvant-rich cell wall it would be
surprising if it did not have effects on the human immune
system beyond inducing immune responses directed at
the tubercle bacillus. Indeed, commencing in 1935 [69],
numerous attempts have been made to use BCG as an im-
munotherapeutic agent for treatment of cancer though,
with the notable exception of superficial bladder cancer,
with very variable and generally disappointing results [70].
By contrast, there have been several reports that BCG
vaccination affords a useful degree of protection against
leukaemia and certain other malignancies in children. Theearly reports, commencing in 1970, generated consider-
able controversy with conflicting data being reported by
different workers. When, however, the data from all
published reports were compared, it became apparent
that protection against leukaemia was conferred in those
settings in which BCG was administered very early in life
and/or where vaccination conferred significant protection
against tuberculosis [71].
In Finland it was shown that a positive tuberculin reac-
tion indicative of infection by Mycobacterium tuberculosis
or vaccination with BCG led to a reduced risk of all types
of leukaemia over a 30 year follow-up period, with natural
infection and BCG vaccination conferring equal levels of
protection [72]. In this context it is possible that natural
infection by Mycobacterium bovis (from which BCG was
derived) protected against leukaemia as a 4.5% annual in-
crease in rates of this disease in Great Britain between
1911 and 1959 has been reported [73]. Notably, 1911 was
the year that bovine tuberculosis eradication measures
commenced in Great Britain and led to a reduction in
viable bovine tubercle bacilli in cows’ milk [74], although
of course there may be alternative explanations for the rise
in the incidence of leukaemia.
There is considerable geographical variation in the
protective efficacy of BCG vaccination against tubercu-
losis, ranging from around 80% to no protection, and even
an increase of disease risk in some regions [75]. A widely
accepted explanation for this variation is that environmen-
tal factors, notably exposure to populations of saprophytic
mycobacteria in the water and soil, are able to prime the
immune system to an inappropriate, Th2 polarized, pat-
tern of reactivity that BCG is unable to reverse and may
even boost [76,77].
‘Failed immune stimulation’ as a melanoma risk factor
and its interplay with other risk factors
There are a number of established melanoma risk factors,
namely light skin pigmentation, intermittent sun exposure
and multiple naevi, with some other candidate factors
which are currently being investigated, such as exposure
to heavy metals, polychlorinated biphenyls, pesticides, and
genetic factors modifying response to environmental fac-
tors [78]. The potential protective effect of infections and
vaccinations on cancer and cancer risk and progression of
melanoma has, until recently, been largely neglected.
In the 1990s Kölmel and colleagues established a working
group – Febrile Infections and Melanoma (FEBIM) –
within the European Organization for Research and
Treatment of Cancer (EORTC). Based on a pilot study
[79] this group undertook a series of studies to establish
the relationship between the risk for developing melan-
oma and a history of, initially, infectious diseases [80],
and, subsequently, also of vaccinations [81,82]. The study
cohort included 603 cases and 627 population controls
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within each of a total of 11 study centres in six European
countries and in Israel. The recruitment period for the
investigation lasted from 1994 to 1997. The study in-
vestigated the effect of febrile infections and of certain
vaccinations on the risk to develop melanoma as well
as the duration of a risk reducing effect of the vaccinations
and on possible synergistic, cumulative or non-cumulative
effects of vaccinations and infections. Established melan-
oma risk factors (see above) were also determined and
adjustments were made for these factors as well as for
gender and age.
In the first report of the FEBIM group a significant
level of protection against melanoma in those with a
history of certain severe infections (sepsis, Staph. aureus
infection, pneumonia, pulmonary tuberculosis) with fever
of over 38.5°C was demonstrated [80]. It should, however,
be noted that these apparently melanoma-protective infec-
tious diseases have become rare in the industrialized na-
tions. A subsequent study report included the history of
vaccinations and demonstrated protection with an odds
ratio of risk of 0.4 (95% confidence interval 0.18-0.85) in
those vaccinated with BCG alone, 0.6 (95% CI 0.36-0.99)
in those vaccinated with vaccinia alone and 0.41 (95% CI
0.25-0.67) in those receiving both vaccines [81]. The vac-
cines were both administered early in life and were associ-
ated with a long-lasting relatively strong protective effect
against melanoma in the age group < 50 years with a wan-
ing of protection in older subjects (age group ≥ 50 years)
but with a cumulative protective effect in those receiving
both vaccines [81] (Table 1). Joint analyses of vaccinations
and a history of serious infectious diseases (s) likewise
exhibited a cumulative effect of the weaker protections
[83] (Table 2).
Joint analyses of ‘vaccinated or not vaccinated with
BCG and/or vaccinia’ (Table 3) with established melanoma
risk factors showed synergisms or, in other words, indicated
a substantial potential of these vaccinations to neutralize –
at least in part – one or two major environmental melan-
oma risks indicated by skin type (according to Fitzpatrick)
and number of sunburns in life, respectively, representing
vulnerability of the skin by ultraviolet light and injury
caused by it [83].
The relation of ‘vaccinated or not vaccinated with BCG
and/or vaccinia’ with indicators of genetic melanoma risk,Table 1 Joint effects of vaccination with BCG and vaccinia on
Co-variable Only BCG
Age group
<50 years 0.23 (0.05-0.91) n = 25
≥50 years 0.74 (0.25-2.28) n = 20
aWith respect to two age groups, <50 and ≥50 years. Data expressed as Odds Ratio
freckling index, number of naevi and number of sunburns. n = number of cases anas indicated by number of naevi and number of freckles,
respectively, was less straightforward. However, com-
parison of the reference of the supposed genetic risk
indicators with the highest categories in the joint ana-
lyses led to the categorization as ‘non-cumulative’.
This was a rather surprising observation.
Interpretations of the FEBIM study
The FEBIM study led to the conclusion that vaccination
with BCG and/or vaccinia over-rides a major genetic risk
factor such as the expression of an oncogene involved in
the pathogenesis of melanoma.
In principle all the findings of the study could be ex-
plained in at least two different ways. First, these vaccines
may substitute for natural contact with micro-organisms
for inducing regulatory mechanisms in the immune system
[82,83]. Secondly, the vaccines may generate cross-reacting
immune responses directed on one or more epitopes
expressed on potential precursor cells of many or all
melanomas and eventually also on malignantly transformed
melanoma cells. These two explanations are not mutually
exclusive.
In support of the second explanation, a search of gene
data bases by use of the Basic Local Alignment Search Tool
(BLAST) showed that the relevant pathogens and vaccines
(BCG and vaccinia) with a demonstrable protective effect,
but not pathogens and vaccines not associated with protec-
tion, have epitopes homologous with HERV-K-MEL, an
epitope encoded by a human endogenous retrovirus of the
K series (HERV-K) [83,84]. This epitope is expressed in the
majority of melanomas, as well as on cells of atypical naevi
(presumed potential precursors of melanoma), and to a
lesser extent in certain other cancers, and is capable of
generating CD8+ T-cells directed towards potential precur-
sor cells of melanoma [84]. In this context there is evidence
that expression of HERV-K in melanocytes can result in
malignant transformation [85], and a mechanism could be
the generation of an abnormal melanin capable of inducing
harmful long living reactive oxygen species which may also
have relevance to other disease processes, such as multiple
sclerosis in which HERV expression occurs [86]. It should
be noted that the putative oncogene is not the HERV-K-
MEL peptide but the HERV-K-ENV protein, both being
genetically encoded by the same gene complex though in
different open reading frames.melanoma riska
Only vaccinia Both
0.31 (0.07-0.98) n = 111 0.27 (0.09-0.80) n = 299
0.69 (0.38-1.22) n = 362 0.48 (0.26-0.86) n = 313
s (95% Confidence interval), adjusted for centre, sex, ethnic origin, skin type,
d controls. Summarized from the FEBIM study [81].
Table 2 Joint effects of vaccination with BCG and/or vaccinia with history of serious infectious disease on melanoma
riska
Co-variable serious infectious disease Vaccination with BCG and vaccinia Concomitant effect (type of)
Yes No
≥1 1.00 n = 96 1.21 ((0.67-2.06) n = 12
0 1.12 (0.30-4.30) n = 516 3.03 (1.58-5.97) n = 88 Cumulative
Vaccination with BCG or vaccinia
Serious infectious disease
Yes No
≥1 1.00 n = 98 1.97 (1.14-3.56) n = 12
0 1.28 (0.35-4.90) n = 420 3.45 (1.79-6.80) n = 89 Cumulative
aData expressed as Odds Ratios (95% Confidence intervals), adjusted for centre, sex, age, ethnic origin, skin type, freckling index, number of naevi and number of
sunburns. n = number of cases and controls. Summarized from the FEBIM study [82,83].
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ated expanded populations of specific T-cells cross-reactive
with the HERV-K-MEL epitope. The situation has some
analogy to the use of the human papilloma virus vaccine to
prevent cervical cancer, except in the case of melanoma the
target virus is not a replicating one and is endogenous ra-
ther than exogenous. It must also be emphasized that here
(in case of the supposed inducible melanoma immune sur-
veillance) endogenous and exogenous risks are merging
into one and it remains a question whether and how they
could be separated clearly from each other.
As, however, vaccinia vaccination is no longer used
(vaccination of the general populations ceased aroundTable 3 Joint analyses of the melanoma risk indicator ’not be




III/IV 1.00 n = 607
II 1.80 (1.18-2.78) n = 396
I 1.54 (1.16-2.05) n = 126
Sunburns in life
0 1.00 n = 338
1-5 0.93 (0.68-1.26) n = 596
>5 1.39 (0.91-2.14) n = 191
Naevi
0 1.00 n = 272
1-4 1.05 (0.70-1.48) n = 387
>4 1.56 (1.10-2.22) n = 456
Freckles on arm
0 1.00 N = 457
10-20 1.57 (1.17-2.10) n = 426
>20 3.03 (2.13-4.35) n = 247
aCompared with ‘vaccinated with BCG and/or vaccinia’. Data expressed as Odds Rat
and other known risk factors. n = number of cases and controls. Summarized from1975) and neonatal BCG vaccination is currently restricted
to certain ethnic groups and localities (although the
upsurge of extreme resistant tuberculosis may lead to
its more extensive use in the future) an alternative
cheap and safe vaccine would be preferable for the
prevention of melanoma. The same analysis used to
identify the homologous epitopes to HERV-K-MEL in
vaccinia and BCG vaccines also revealed a homologous
epitope, with similar anchor sequences for HLA pres-
entation, in the 17D yellow fever vaccine (YFV) [83].
Moreover, the induction of an anti-melanoma immune
response was observed in Rhesus macaques vaccinated
with YFV [87].ing vaccinated with either BCG or vaccinia’ and four
Concomitant effect (type of)
No
1.68 (0.93-3.05) n = 58
2.15 (0.65-8.34) n = 30
6.37 (3.50-19.64) n = 12 Synergistic
1.51 (0.76-3.01) n = 46
2.29 (1.14-4.76) n = 45
5.30 (0.87-102.48) n = 8 Synergistic
2.51 (1.16-5.77) n = 35
5.24 (1.89-17.10) n = 22
1.71 (0.84-3.57) n = 42 Non-cumulative
3.26 (1.60-6.87) n = 39
2.38 (1.09-5.32) n = 31
4.06 (1.78-10.17) n = 30 Non-cumulative
ios (95% Confidence Intervals) for melanoma risk, adjusted for centre, sex, age,
the FEBIM study [83].
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mouse-melanoma model
In human beings the endogenous retroviral ENV gene
[88], and the spatially closely related MEL gene [84], of
HERV-K (the latter coding only for a peptide) can be
expressed in human cells but, in contrast to the melanoma
cells and their presumed precursors, are typically not
found in normal cells. Anchor sequences of the hypothet-
ical MEL peptide should facilitate its presentation, in
particular by the HLA-A2 molecule that is present in
about 70% of the European population. Besides melan-
oma, chronic lymphatic leukaemia, lymphomas and breast
cancer express HERV-K antigens more frequently than
healthy tissues [84,89-91], and thus require consideration
in this debate.
Current concepts in immunology indicate that vaccin-
ation does not just evoke immune responses to exogenous
pathogens but can elicit immune responses and induce
immune regulatory networks affecting endogenous (self-
specific) epitopes [92-94]. In this context, the murine
colorectal carcinoma CT26 and melanoma B16 express,
respectively, products of the endogenous retroviral genes
gp70 and p15E which are recognized by T cells and when
animals with lung metastases due to these tumours were
inoculated with dendritic cells pulsed with these endogen-
ous antigens significant tumour inhibition was observed
[95]. It must, however, be acknowledged that while
vaccinia, BCG and the experimental mouse vaccines
seem to reduce the risk of developing melanoma they have
little or no potential for therapy of established tumours.
Postulated critical aspects of cancer protective immunity
inducible by vaccination
The ultimate question as to how immune reactivity
prevents certain cancers has not yet been answered but
several pointers to the answer have become apparent
and merit further study. In this context it is noteworthy
that prevention of malignant diseases, in particular of
melanoma, seems to be achieved much more easily than
the control of established disease by immunotherapy [96].
Moreover, prevention of melanoma by prior vaccination
with BCG, vaccinia and/or YFV appears likely to rely on
processes operating at a time before immune tolerance
is induced. Establishment of immune tolerance in the
tumour micro-environment is an essential element of
tumour survival and progression and, once established,
it is difficult to break [97,98]. The attrition of local and
of general immunity has been linked to chronic inflamma-
tion, and immune suppression is mediated by myeloid-
derived suppressor cells, type-2 cytokine expression and
alternatively activated, M2, macrophages that protect
tumours from immune recognition and attack [40].
Furthermore, with respect to the ‘biography’ of the im-
mune system, there is increasing evidence that cancer isassociated with the nature and function of regulatory and
helper T-cells, including a local and more general Th1 to
Th2 shift [67,68,99]. Indeed, the characterisation of the
types of tumour-infiltrating T-cells and macrophages ap-
pears to provide a clearer prognostic indicator than the
conventional classifications based on extent and spread of
disease [100].
A subset of CD8+ T-cells, the CD8 (+) CD44 (high)
cells, are self-specific and appear to play a unique role in
surveillance of host cells that have been altered by in-
fection or malignant transformation [93]. Although in
experimental settings these cells can be transformed by
cytokines such as interleukin-2 to operate in a cytotoxic
mode, it is uncertain whether a lasting therapeutic effect
can become induced. For prevention it is more likely that
another effector mechanism is involved; one that is not
cytotoxic but suppresses the genetic expression of a gene
such as the HERV-K-ENV postulated to be involved in
oncogenesis [83,99]. This might be described as a kind of
immune repair operating at the time around tumour initi-
ation. The self-specific immunity may not just be medi-
ated by the specific CD8+ T-cells mentioned above but
also by a subset of gangliosides, in particular some of the
neo-lacto series, that are shed by interacting macrophages
directly to the target cells [101-103].
The ‘biography’ of the immune system and control of
cancer
Immune memory in respect to protection against mel-
anoma resulting from vaccinations early in life is clearly
long-lasting. Vaccination with vaccinia and/or with BCG
in early childhood resulted in a strongly reduced risk of
melanoma in the age-group up to 50 years (OR = 0.27,
95% CI: 0.09-0.80) and the protection extended, though
with reduced strength, beyond the age of 50 years (OR =
0.48, 95% CI: 0.26-0.86) [81].
Around 95% of the European population was vaccinated
with vaccinia until about 1975 when it was terminated
and around 50% received BCG vaccine until about 1990
when it was phased out except in certain high-risk groups
in some countries. If the findings of the FEBIM study are
correct, the consequence of these changes in vaccination
strategies could be a continued rise in the incidence and
risk of melanoma. The risk may be further enhanced by a
reduction in the background protection induced by de-
clined exposure to infectious and environmental agents.
In the past, the major plagues may indeed have been
important as inducers of melanoma-preventing im-
mune responses among the survivors. Homologies to
the HERV-K-MEL sequence, the postulated target of
the induced immune responses, were also found to be
present in the causative agents of all the plagues that
declined markedly in prevalence in the late 19th or early
20th century; namely, yellow fever, cholera, smallpox,
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scarlet fever. Not all strains of streptococci express the
HERV-K-MEL epitope [83], possibly explaining why
Coley’s therapy with Streptococcus pyogenes was rather
variable in effect until he added Serratia marcescens,
which has an epitope with good homology with HERV-K-
MEL. In this context, a case of regression of an advanced
metastatic melanoma following diphtheria-pertussis-tetanus
vaccination has been described and, in a discussion of
possible mechanisms it was observed that homologous
peptides to HERV-K-MEL are present in the three com-
ponents of this vaccine [104].
A possible melanoma protective effect of vaccination
with yellow fever 17D
A study was undertaken in the Veneto, Northern Italy,
where the administration of the yellow fever 17D vaccine
is strictly documented, to determine whether this vaccine
might likewise confer protection against melanoma [105].
As, in general, only those intending to travel to tropical
countries are vaccinated against yellow fever, confounding
factors are introduced as there are socio-economic differ-
ences between vaccinated and unvaccinated groups which
could affect the risk of melanoma [106].
Accordingly, the analysis was performed within the
vaccinated group (n = 28,306) by comparing melanoma
with cancers not expressing the HERV-K-MEL epitope
and this revealed a significant reduction in the risk of
melanoma among those vaccinated 10 or more years
previously [105]. The odds ratios and 95% confidence
intervals (CI) were calculated by means of logistic re-
gression models. Odds ratios in the 0–4, 5–9 and ≥ 10
year time since vaccination (TSV) groups were, respect-
ively, 1.00, 0.96 (CI 0.29–1.67) and 0.26 (CI 0.07-0.96).
In an interim report from an ongoing follow-up of the
Italian cohort (n = 27,905 vaccinees, 401 were not traced)
the follow-up time was extended from 31 December 2001
to 31 December 2005 [107]. Person-years (PY) were
broken down to five-year classes of age, gender, and
TSV. The percentage of PY between 18 and 64.9 years
of age was 93% in the cohort and 68% in the general
Veneto population in 1996 (mid year of the observation
period 1987–2005), while the percentage of population
aged 65+ years were 7% and 17% in the cohort and Veneto
population, respectively. Within the cohort, the percent-
ages of males and females were similar both before 65
years of age (93% vs. 93%) and after 65 years of age (7% vs.
7%). Moreover, the percentages of PY above 65 years of
age were 6% and 12%, respectively, in the first and second
class of TSV. Therefore PY tend to increase with TSV and
the two variables are correlated with each other.
The record-linkage with VTR data returned 57 cases
of melanoma (37 in the initial study) and (used as the
control group) 1214 other site cancers (except skincancers), an overall of 1271 cases (830 in the original
study). TSV was broken down in two classes, <10 (n = 46
cases, 799 controls), and ≥ 10 years (N = 11 cases and 415
controls) [107]. The odds ratio and 95% confidence inter-
vals were 1.00 (reference) and 0.48 (0.25-0.95), p = 0.035
and support the original observation. Incidence rate ratio
(IRR) with 95% confidence intervals, calculated with
Poisson regression, was 0.59 (0.30-1.16), p = 0.10.
Subsequently, an independent study on the protective
effect of yellow fever vaccination on melanoma was con-
ducted on subjects on active duty in the armed forces in
the United States (US) who had received YFV or other
vaccinations between January 1, 1999, and June 30, 2009
[108]. The study included 638 cases of melanoma and
6,372 healthy matched controls and showed a lowering
of the risk of melanoma in the vaccinated TSV ≥10 year
group, with an odds ratio of 0.70 (95% CI 0.29–1.67) but
this was not statistically significant.
One advantage of the US study was that it involved a
much more homogeneous population than that in the
Italian study, thus removing many confounding factors
and permitting a direct comparison of those vaccinated
or not vaccinated with YFV. A weakness, however, was
that the maximum time since vaccination (TSV) was
only 11.5 years, with only 14.9% of subjects being in the
TSV ≥ 10 year-group, whereas the maximum TSV in the
Italian study was 22.6 years, and it was demonstrated
that protection was only evident in the ≥10 year group.
It is possible therefore that a follow-up study in the US
might demonstrate a significant level of protection in
the ≥10 year group.
The data from the Italian study indicate the need for
further studies and if the results of this study reflect the
real situation they give support to the concept that, in
order to have a protective effect, vaccination (whether
BCG, vaccinia or YFV) must be given at or before the
time of the initiation of the malignant process, long before
clinical manifestation of the disease which, in the case of
melanoma is about 10 years [59,105].
Effect of prior vaccination on the clinical course of
melanoma
As an important and unique extension of the FEBIM
study, the effect of infections and vaccination with BCG
and vaccinia on the progression of melanoma in those in
whom the disease was not prevented was investigated
(the prospective study arm) [109]. From the initially re-
cruited 603 patients from 11 centers in six European
countries and Israel 30 patients classified as having
melanoma in situ were omitted from the follow-up and
31 (5%) of the patients were lost for the follow-up.
Thus the outcome of 542 patients was evaluated. The
survival of the patients, after surgery, who had been vacci-
nated with vaccinia, BCG or both was significantly better
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Figure 2.
Importantly, the differences shown in Figure 2 persisted
after adjustment for several prognostic factors in a multi-
variate analysis. This is of importance for the appraisal of
the study results, as otherwise it cannot be excluded that
the differences between the unadjusted survival curves are
merely due to bias from confounding factors. For example,
social status may well be related to a willingness to partici-
pate in early detection programs, resulting in different
tumour stages at the first diagnosis of melanoma.
This finding is without precedent. One possible explan-
ation is that the development of a malignant disease such
as melanoma is typically not the result of a single process
but to an evolutionary progression involving several pro-
cesses occurring at different stages of the disease. This can
be understood in relation to the concept, discussed above,
of ‘immunoediting’ as the tumour evolves through the
stages of elimination, equilibration and escape, and which
continues after clinical presentation [35]. Thus immune
responses that are unable to prevent initial elimination
and subsequent escape of a tumour from a state of equi-
librium may nevertheless inhibit later events such as local
invasiveness and the establishment of metastases.
Another possibility is suggested by the recent observation
that expression of the HERV-K-ENV gene, being closely
associated with the HERV-K-MEL, leads via the ENV
peptide to the generation of atypical multinucleate cells
which have growth and survival advantages, contribut-
ing to tumour progression [110]. Elimination or repair
of cells expressing this peptide by CD8+ cytotoxic cells
could therefore be advantageous to the patient.Figure 2 Kaplan-Meier estimates for overall survival of melanoma
patients enrolled immediately after excision of the primary
tumour, from reference [109].Discussion
Prior claims that BCG vaccination affords protection
against certain malignancies have been reviewed, together
with the results of the more recent FEBIM study. In the
latter study, infections and a broader range of vaccina-
tions, including vaccinia, which may have conferred
protection, have been investigated and adjustments
were made for other risk factors. Moreover, the subse-
quent studies on yellow fever vaccination [105,107], gave
a preliminary indication that YFV in adults might also
contribute to such protection, although confirmative stud-
ies are required especially as a nested case approach and
has to be handled with great caution [111].
On the other hand, there are advantages in features of
the nested case approach as used addressing a possible
tumour protective potential of yellow fever vaccination
[105,107]. The study design has advantages as it ensures
that patients and controls are coming from the same
source group of persons, thus minimizing diverse con-
founding factors such as those resulting from differences
in the socio-economic status. Since, however, the controls
also have various tumours, the relevance of the observed
protection to the general population is uncertain [112].
Nevertheless, such studies could give answers to the
following questions.
○ Does yellow fever vaccination afford protection
against any other malignancies?
○ Is there indeed an association between expression of
HERV-K genes within the tumours and protective
efficacy of vaccination and, if so, is this a necessary
or sufficient condition?
○ Could the risk of breast cancer, which often
expresses HERV-K ENV [90], be prevented by BCG
or yellow fever vaccination?
○ Is the time interval between vaccination and onset of
protection the same for all malignancies?
○ What is an appropriate age for vaccination in order to
achieve optimal benefit?
The latter also raises the question whether there is an
age group of persons in specific need of such vaccination
(s) while other age groups might have sufficient protection
from alternative (environmental) immune contacts.
The yellow fever vaccine has many advantages over
other currently available vaccines, as it is not only one of
the most effective vaccines ever developed [113] but is
cheap and relatively safe [114]. Indeed, in the 70 years or
more elapsed since its development, YFV 17D has been
administered to over 540 million people globally, with
very rare (1 in 250,000) cases of serious adverse events and
it can, in principle, induce protective immunity persisting
up to 40 years [114], although re-vaccination is recom-
mended after 10 years. Whereas BCG vaccination is most
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tuberculosis), YFV can be administered to adults, thereby
addressing the age group most at risk of cancer.
Vaccinia vaccination is now principally of historical
interest. However, since the vast majority of humans have
been vaccinated in early childhood until about 1975 this is
still to be considered in all studies investigating a possible
protective effect against malignancies. The case of BCG
and possibly of the newer mycobacterial vaccines under-
going evaluation is different. BCG in newborns is still in
use in many tropical countries and newer non-replicating
vaccines might find a use in adults. Therefore it is highly
desirable that all future studies on risk factors for melan-
oma and other malignancies should investigate in parallel
the status of vaccination with BCG, vaccinia and yellow
fever.
The observation that BCG (and, historically, vaccinia)
vaccination early in life improved the prognosis of patients
after surgical therapy of melanoma is of practical import-
ance as the prognosis of inoperable melanoma is poor.
Further studies are required to determine whether BCG
vaccination has a similar beneficial effect in other forms
of cancer. We therefore open the debate as to whether
extensive controlled vaccination studies should be under-
taken in patients and/or regions for whom/where they are
needed most urgently.Summary
The journey from Saint Peregrine’s ‘miraculous’ cure to
contemporary vaccination strategies for the prevention
or cure of malignant disease has been a long one and,
unfortunately, it is supported so far mostly by observa-
tional studies as reviewed above rather than by mech-
anistic ones. Nevertheless, the more recent studies
including those by the FEBIM group suggest that mea-
sures for prevention of some malignancies such as melan-
oma and some forms of leukaemia are already at hand:
BCG vaccination of new-borns and (for melanoma) YFV
of adults. We concede that the evidence of their benefit
for prevention of malignancies needs to be strengthened
by further studies and, as some other cancers also express
HERV-K epitopes [84,89,90,111,115], these could likewise
be the subjects of further studies. Such studies could well
pave the way to the development of recombinant vaccines
with improved and extended properties and these might
well be based on YFV, mycobacterial and/or vaccinia
vaccines.Abbreviations
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